Annovis Bio (ANVS) Research & Development (2019 - 2026)
Annovis Bio (ANVS) posted Research & Development of $16.7 million for Q1 2026, up 91.07% sequentially from $8.8 million in Q4 2025, and up 233.64% YoY from $5.0 million in Q1 2025.
Annovis Bio (ANVS) Research & Development (2019 - 2026) Analysis & Trends
Annovis Bio has reported Research & Development for 8 years, with the latest figure at $16.7 million in Q1 2026.
- Quarterly Research & Development rose 233.64% year-over-year to $16.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $36.9 million (up 99.75% YoY) and the FY2025 annual result came in at $25.2 million, up 26.11% from the prior year.
- Research & Development improved to $16.7 million in Q1 2026 per ANVS's latest filing, from $8.8 million in the prior quarter.
- Over five years, Research & Development peaked at $16.7 million in Q1 2026 and troughed at $2.1 million in Q1 2022.
- A 5-year average of $6.9 million and a median of $6.2 million in 2022 frame the typical range for Research & Development.
- The sharpest annual moves came in 2023 and 2024: Research & Development soared 262.2% in 2023, then plunged 80.56% in 2024.
- Over 5 years, Research & Development stood at $6.2 million in 2022, then soared by 43.43% to $8.9 million in 2023, then tumbled by 43.87% to $5.0 million in 2024, then soared by 75.07% to $8.8 million in 2025, then surged by 91.07% to $16.7 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $16.7 million, $8.8 million, and $6.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Annovis Bio | 66.78 Mn | 66.78 Mn | - | 12.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 16.72 Mn |
| Dec 31, 2025 | 8.75 Mn |
| Sep 30, 2025 | 6.29 Mn |
| Jun 30, 2025 | 5.16 Mn |
| Mar 31, 2025 | 5.01 Mn |
| Dec 31, 2024 | 5.00 Mn |
| Sep 30, 2024 | 2.69 Mn |
| Jun 30, 2024 | 5.79 Mn |
| Mar 31, 2024 | 6.51 Mn |
| Dec 31, 2023 | 8.90 Mn |
| Sep 30, 2023 | 13.84 Mn |
| Jun 30, 2023 | 8.26 Mn |
| Mar 31, 2023 | 7.79 Mn |
| Dec 31, 2022 | 6.21 Mn |
| Sep 30, 2022 | 4.12 Mn |
| Jun 30, 2022 | 4.03 Mn |
| Mar 31, 2022 | 2.15 Mn |
| Dec 31, 2021 | 2.88 Mn |
| Sep 30, 2021 | 1.38 Mn |
| Jun 30, 2021 | 1.82 Mn |